



Vivimed

Investor Release

Strides Vivimed JV receives approval for Albendazole Tablets**Second generic approval by US FDA for Albendazole Tablets Product to be launched immediately**

Hyderabad, India, December 12, 2018 – Vivimed Labs Limited (Vivimed) today announced that its 50:50 JV Strides Vivimed Pte. Ltd, Singapore has received approval for Albendazole Tablets USP 200mg from the United States Food & Drug Administration (US FDA). This is the second generic approval by US FDA for Albendazole Tablets.

Albendazole Tablets is a generic version of Albenza Tablets® of Amneal Pharmaceuticals, Inc. According to IQVIA MAT data, the US market for Albendazole Tablets USP 200 mg is approximately US\$ 100 Mn.

About Albendazole Tablets:-

Albendazole is an anthelmintic medication used to treat certain infections caused by tapeworm. Albendazole prevents newly hatched insect larvae (worms) from growing or multiplying in the body.

About Vivimed Labs:

Vivimed is a Pharmaceuticals and Specialty Chemicals company headquartered in Hyderabad, India. It has manufacturing footprint across India, Europe and North America across its line of business and employs close to 2000 personnel across the world. Vivimed reported sales of about INR 12 bn for the financial year ended March 31, 2018.

For further information on Vivimed, visit www.vivimedlabs.com

*** **

For VIVIMED LABS LTD.

Company Secretary




Vivimed

Safe Harbour

This release contains “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Vivimed’s future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Vivimed undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For further information please contact	
Company Contact: Vivimed Labs Limited CIN No: L02411KA1988PLC009465 Sunil Arab, VP Corporate Strategy Phone: 040-66086608 Email: sunil.arab@vivimedlabs.com	Investor Relations: Citigate Dewe Rogerson Communications Pvt Ltd. CIN No: U67190MH1999PTC119332 Gavin Desa / Suraj Digawalekar Phone: +022 6645 1237 / 19 E-Mail: gavin@cdr-india.com E-Mail: suraj@cdr-india.com

For VIVIMED LABS LTD.


Company Secretary